The market is segmented based on , By Type (Spinocerebellar Ataxias, Ataxia-Telangiectasia, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), Product (Treatment and Diagnosis), Dosage Form (Solid, Liquids, and Others), Route of Administration (Oral, Parenteral, and Others), Patient Type (Adult, Child, and Geriatric), End User (Hospital, Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2029.
.
The Global Ataxia Market size was valued at USD 22631.81 USD Thousand in 2021.
The Global Ataxia Market is projected to grow at a CAGR of 6.9% during the forecast period of 2022 to 2029.
The major players operating in the market include Novartis AG, Merck KGaA, Aurobindo Pharma., Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Acorda TherapeuticsInc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin., Amneal Pharmaceuticals LLC., Apotex Inc., Cipla Inc., Biovista, Design Therapeutics Inc., Reata PharmaceuticalsInc., MATRIX BIOMED, Intrabio, Biohaven Pharmaceuticals, Retrotope Inc., Adverum BiotechnologiesInc., Priory., Sutter Health., Upstream Rehabilitation Inc., Banner Health, Select Medical Corporation, ATI Physical Therapy, .
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Switzerland, Ireland, Russia, Hungary, Austria, Norway, Poland, Turkey, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait, Rest of the Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.